DE60235535D1 - Aminderivat mit kaliumkanalregulierender funktion, dessen herstelung und verwendung - Google Patents

Aminderivat mit kaliumkanalregulierender funktion, dessen herstelung und verwendung

Info

Publication number
DE60235535D1
DE60235535D1 DE60235535T DE60235535T DE60235535D1 DE 60235535 D1 DE60235535 D1 DE 60235535D1 DE 60235535 T DE60235535 T DE 60235535T DE 60235535 T DE60235535 T DE 60235535T DE 60235535 D1 DE60235535 D1 DE 60235535D1
Authority
DE
Germany
Prior art keywords
derivativity
amine
production
regulating function
channel regulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60235535T
Other languages
English (en)
Inventor
Hai Wang
Rifang Yang
Chaoliang Long
Liuhong Yun
Wenyu Cui
Lin Wang
Huasong Feng
Qixiu Gao
Xinqiang Lu
Fulin Li
Gang Hu
Lijun Liu
Xingchun Tang
Rusheng Zhao
Yuan Yan
Huamei He
Wei Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Pharmacology and Toxicology of AMMS
Original Assignee
Institute of Pharmacology and Toxicology of AMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN 01101656 external-priority patent/CN1250519C/zh
Priority claimed from CN 01101655 external-priority patent/CN1250518C/zh
Application filed by Institute of Pharmacology and Toxicology of AMMS filed Critical Institute of Pharmacology and Toxicology of AMMS
Application granted granted Critical
Publication of DE60235535D1 publication Critical patent/DE60235535D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/08—Monoamines containing alkyl groups having a different number of carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
DE60235535T 2001-01-19 2002-01-21 Aminderivat mit kaliumkanalregulierender funktion, dessen herstelung und verwendung Expired - Lifetime DE60235535D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN 01101656 CN1250519C (zh) 2001-01-19 2001-01-19 具有调节钾通道功能的胺衍生物及其制备方法和应用
CN 01101655 CN1250518C (zh) 2001-01-19 2001-01-19 具有抗神经缺血缺氧损伤作用的胺衍生物及其在医药学中的应用
PCT/CN2002/000029 WO2003080556A1 (fr) 2001-01-19 2002-01-21 Derive d'amine a fonction regulatrice des canaux potassiques, sa preparation et son utilisation

Publications (1)

Publication Number Publication Date
DE60235535D1 true DE60235535D1 (de) 2010-04-15

Family

ID=28455393

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60235535T Expired - Lifetime DE60235535D1 (de) 2001-01-19 2002-01-21 Aminderivat mit kaliumkanalregulierender funktion, dessen herstelung und verwendung

Country Status (7)

Country Link
US (1) US7560473B2 (de)
EP (1) EP1386908B1 (de)
JP (1) JP4279685B2 (de)
KR (2) KR20090028654A (de)
AU (1) AU2002226266A1 (de)
DE (1) DE60235535D1 (de)
WO (1) WO2003080556A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2477604A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
EP2404605B1 (de) 2004-08-25 2015-04-22 Essentialis, Inc. Pharmazeutische Formulierungen von Kalium-ATP-Kanalöffnern und deren Verwendungen
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP1843734A4 (de) 2005-02-03 2008-09-10 Signum Biosciences Inc Zusammensetzungen und verfahren zur intensivierung kognitiver funktionen
WO2006088875A2 (en) * 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Intranasal administration of modulators of hypothalamic atp-sensitive potassium channels
JP5543110B2 (ja) * 2006-01-05 2014-07-09 エッセンシャリス，インク． カリウムａｔｐチャネルオープナの塩およびその使用
AU2012203517B2 (en) * 2006-01-05 2014-04-24 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
US20070231273A1 (en) * 2006-03-31 2007-10-04 Jie Wu Method for Decreasing Blood Glucose Levels
CN101795691A (zh) * 2007-07-02 2010-08-04 伊森舍丽斯有限公司 钾atp通道开放剂的盐及其用途
CN102014897B (zh) 2008-04-21 2015-08-05 西格纳姆生物科学公司 化合物、组合物和其制备方法
PL2315740T3 (pl) 2008-07-08 2018-05-30 Catabasis Pharmaceuticals, Inc. Salicylany acetylowane kwasem tłuszczowym i ich zastosowania
US9085527B2 (en) 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
US20100082490A1 (en) * 2008-09-30 2010-04-01 Apple Inc. Systems and methods for secure wireless transactions
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
CN102724877B (zh) 2009-09-01 2015-05-13 凯特贝希制药公司 脂肪酸烟酸缀合物及其用途
WO2011044138A1 (en) * 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Lipoic acid acylated salicylate derivatives and their uses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB873780A (en) 1959-03-28 1961-07-26 Bayer Ag New secondary amines
US3067101A (en) 1959-11-25 1962-12-04 Lilly Co Eli Method for controlling hypertension
US3168567A (en) 1960-02-29 1965-02-02 Lilly Co Eli Hindered alkyl and alkylene secondary amines
DE1197091B (de) 1960-08-25 1965-07-22 Studiengesellschaft Kohle Mbh Verfahren zur Herstellung von N-(tertiaer Alkyl)-aminen
US3152180A (en) * 1960-08-25 1964-10-06 Studiengesellschaft Kohle Mbh Process for the production of nu-tert-alkyl amides and, if desired, nu-tert. alkyl amines
US3673249A (en) 1970-06-09 1972-06-27 American Cyanamid Co Process for preparing tertiary amyl urea
JPS4836129A (de) 1971-09-16 1973-05-28
DE2338087A1 (de) * 1973-04-30 1975-01-16 Albert Ag Chem Werke Neue aldonsaeureamide als arzneimittel
US4157257A (en) 1976-10-01 1979-06-05 Utsunomiya University Benzenesulfonamide derivatives
EG18833A (en) 1988-12-09 1994-11-30 Kumiai Chemical Industry Co Cyclic amide compounds and herbicides
WO1995022327A1 (en) 1994-02-22 1995-08-24 Knoll Ag Use of 1-(arylalkylaminoalkyl) imidazoles for treating neurological damage
AU1649900A (en) 1998-12-18 2000-07-12 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use

Also Published As

Publication number Publication date
EP1386908A1 (de) 2004-02-04
KR20030090625A (ko) 2003-11-28
US20040266822A1 (en) 2004-12-30
JP2005519974A (ja) 2005-07-07
KR100939243B1 (ko) 2010-01-29
US7560473B2 (en) 2009-07-14
EP1386908B1 (de) 2010-03-03
KR20090028654A (ko) 2009-03-18
WO2003080556A1 (fr) 2003-10-02
JP4279685B2 (ja) 2009-06-17
EP1386908A4 (de) 2006-07-12
AU2002226266A1 (en) 2003-10-08

Similar Documents

Publication Publication Date Title
DE60235535D1 (de) Aminderivat mit kaliumkanalregulierender funktion, dessen herstelung und verwendung
DE60238358D1 (de) Naturkautschuk-masterbatch dessen Herstellungsverfahren, und Naturkautschukzusammensetzung
ATE424202T1 (de) Substituierte 2-thio-3,5-dicyano-4-phenyl-6- aminopyridine und ihre verwendung
DE50207849D1 (de) Substituierte 2-oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre verwendung
IS2944B (is) Fjölliðu-samrunaefnasambönd með minnkaða mótefniseiginleika, aðferðir við tilbúning og notkun þeirra
DE60227390D1 (de) Dehnbarer vliesstoff und methode zu dessen herstellung
DE602004029483D1 (de) Wässrige dispersion, herstellungsverfahren dafür und verwendung davon
DE60103182D1 (de) Methansufonamido-benzofuran, herstellungsverfahren und dessen verwendung als synthesezwischenprodukt
EP1617807A4 (de) Substituierte 1,4-diazepine und ihre verwendungen
DE60106151D1 (de) Additionshärtbare Silikonelastomermischungen, ihre Herstellung und Verwendung
DE60237851D1 (de) Modifiziertes Propylenpolymer, dieses enthaltende Zusammensetzung und deren Verwendung
DE60235547D1 (de) En daraus, deren herstellung und verwendung
AU2002951274A0 (en) Methods for the chemical and physical modification of nanotubes, methods for linking the nanotubes, methods for the directed positioning of nanotubes, and uses thereof
IL158115A0 (en) Sapogenin derivatives, their synthesis and use, and methods based upon their use
DE60210306D1 (de) Druckregelventil mit einstellmerkmalen
AU2003301066A1 (en) Al2o3-la2o3-y2o3-mgo ceramics, and methods of making the same
DE60105662D1 (de) Strömungsleitelement und Methode zu dessen Herstellung
DE60216345D1 (de) Gummimischung und deren Verwendung
MX272406B (es) Restriccion del paso de fluido y nuevos materiales para el mismo.
EP1621616A4 (de) Menschlicher anti-mensch-interleukin-18-antikörper, fragment davon und verfahren zu deren verwendung
AU2002348998A1 (en) N-methyl-homocystines, use thereof and method for the production thereof
DE50106503D1 (de) Regulierventil mit Voreinstellung
MXPA03007550A (es) Derivados coloporosidos, proceso para su preparacion y su uso.
AU2003276184A1 (en) Gas meter diaphragm, method for the production thereof, and use thereof
AU2002302800A1 (en) Polymeric bead probe with nanocrystal, manufacture and use of the same

Legal Events

Date Code Title Description
8364 No opposition during term of opposition